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Abstract
In a simplified view, members of the HECT E3 family have a modular structure consisting of the C-
terminal HECT domain, which is catalytically involved in the attachment of ubiquitin to substrate
proteins, and N-terminal extensions of variable length and sequence that mediate the substrate
specificity of the respective HECT E3. Although the physiologically relevant substrates of most
HECT E3s have remained elusive, it is becoming increasingly clear that HECT E3s play an important
role in sporadic and hereditary human diseases including cancer, cardiovascular (Liddle's syndrome)
and neurological (Angelman syndrome) disorders, and/or in disease-relevant processes including
bone homeostasis, immune response and retroviral budding. Thus, molecular approaches to target
the activity of distinct HECT E3s, regulators thereof, and/or of HECT E3 substrates could prove
valuable in the treatment of the respective diseases.
Publication history: Republished from Current BioData's Targeted Proteins database (TPdb;
http://www.targetedproteinsdb.com).
Preliminary remarks
HECT E3 ubiquitin-protein ligases have been found from
yeast to humans and range in size from approximately 80
kDa to more than 500 kDa. They are characterized by the
HECT (homologous to E6-AP C-terminus) domain, a C-
terminal region of approximately 350 amino acids in
length with significant similarity to the C-terminus of E6-
AP [1,2]. The HECT domain mediates the interaction with
cognate E2 ubiquitin conjugating enzymes and, via an
evolutionally conserved cysteine residue, forms thioester
complexes with ubiquitin [1-6]. Since the ability to form
ubiquitin thioester complexes in the presence of E2s is
required for their E3 ligase activity, it is commonly
assumed that, unlike members of other E3 families (i.e.
RING finger E3s, U box E3s), HECT E3s play a direct cata-
lytic role in the final attachment of ubiquitin to substrate
proteins [1-9].
While the HECT domain represents the catalytic domain
of HECT E3s [1-3], the substrate specificity of these pro-
teins is assumed to be determined by their respective N-
terminal extensions (see figure 1). Based on the presence
of distinct amino acid sequence motifs within these N-ter-
minal extensions, human HECT E3s can be grouped into
three subfamilies: HECT E3s with RLDs (RCC1-like
domains) (which are termed HERC (HECT and RCC1-like
domain) E3s) [10], HECT E3s with WW domains (termed
Nedd4/Nedd4-like E3s) [11,12] and HECT E3s that nei-
ther contain RLDs nor WW domains (termed SI(ngle)-
HECT E3s) (see figure 1). Since RLDs [13-16] and WW
domains [17-19] represent known protein–protein inter-
action domains, their presence provides some informa-
tion about potential interaction partners of the respective
E3.
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Database analyses indicate that the human genome
encodes 28 different HECT proteins (K. Hoffmann and H.
Scheel, personal communication). Since all of these pro-
teins contain the catalytic site cysteine residue, it can be
assumed that all of these have E3 activity. However,
although this will not be further addressed, one should
keep in mind that the sheer size of HECT proteins could
indicate that, at least in some cases, the function of HECT
proteins may not be restricted to ubiquitylation (i.e.
HECT E3s are multifunctional proteins). In the following,
we will focus on those HECT E3s that have been associ-
ated with human disease, disease-relevant processes, and/
or abnormal phenotypes in mice, and will discuss these
within the context of the abovementioned HECT sub-
families. For a summary of the HECT E3s discussed in this
review see Table 1.
Localization and function
HERC E3s
The human HERC E3 subfamily has six members that,
based on molecular mass, can be further divided into
“large” HERCs (with a molecular mass of more than 500
kDa, i.e. HERC1 and HERC2) and “small” HERCs (with a
molecular mass of approximately 100–120 kDa). The
mRNAs for the various HERCs are expressed in many tis-
sues and the HERC proteins appear to be mainly localized
to the cytoplasm and, from there, to membranous or
vesicular structures. This suggests that, in general, HERC
E3s are involved in membrane traffic pathways (for a
recent review on HERC E3s, see [10]).
The RLD of HERC E3s consists of usually seven repeats of
50–70 amino acids in length and was first described for
the mitotic regulator RCC1 [13]. Structural studies
revealed that RCC1 adopts a seven-bladed β-propeller
structure with each repeat corresponding to one blade
[14]. The RCC1 propeller structure serves at least two
functions: one side of the propeller binds to the GTP-
binding protein Ran and acts as a guanine nucleotide
exchange factor, while the opposite side interacts with
core histones, thus mediating the interaction of RCC1
with chromatin [15,16]. Although it remains to be shown
if the RLDs of HERC E3s also serve dual functions, recom-
binant HERC1 expressed in insect cells was shown to bind
to GTP-binding proteins of the ARF and Rab family [20].
However, it remains unclear if these interactions are
related to the E3 activity of HERC1, since ARF/Rab do not
appear to be ubiquitylated by HERC1. Recently, HERC1
was reported to interact with TSC2, a GTPase-activating
protein of the Rheb GTPase, in murine and human cells,
and to target it for degradation [21]. TSC2 negatively
affects the mTOR pathway and has been associated with
tuberous sclerosis complex, a hereditary disease character-
ized by hamartoma formation in various organs. It
remains to be shown, however, whether HERC1 is
involved in the development of this disease.
Although substrates or interacting partners of HERC2
have not been described, the protein has nevertheless
received considerable attention. Firstly, mutations in the
Herc2 gene have been linked to pathophysiological phe-
The family of HECT E3s Figure 1
The family of HECT E3s. All members of the HECT E3 family are characterized by the C-terminal HECT domain, which con-
sists of approximately 350 amino acid residues and represents the catalytic domain. The HERC family comprises six members, 
which are characterized by the presence of one or several RLD domains (as representative, the structure of HERC5 is sche-
matically shown). The Nedd4/Nedd4-like family has nine members that are characterized by an N-terminal C2 domain and the 
presence of several WW domains (as representative, the schematic structure of Smurf2 is shown). The schematic structure of 
E6-AP, the founding member of the HECT E3 family, is shown as representative of the third subfamily (“E6” denotes the bind-
ing site of E6-AP for the HPV E6 oncoprotein). Members of this subfamily (SI-HECT E3s) are characterized by the notion that 
they contain neither RLDs nor WW domains.BMC Biochemistry 2007, 8(Suppl 1):S6 http://www.biomedcentral.com/1471-2091/8/S1/S6
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notypes in mice (see section on Disease, mutation, expres-
sion, knockout - HERC E3s) [22,23]. Secondly, the human
HERC2 gene is located on chromosome 15q11-13, which
is known as the Prader-Willi/Angelman region [24]. This
region comprises approximately four megabases, is
bounded by duplicons of the HERC2 gene that may pre-
dispose to chromosomal rearrangements and contains a
bipartite imprinting center (and, thus, maternally and
paternally imprinted genes). Prader-Willi syndrome
(PWS) and Angelman syndrome (AS) represent two clini-
cally distinct neurodevelopmental disorders, with PWS
resulting from paternal genetic deficiency and AS from
maternal genetic deficiency [25]. However, since the
HERC2 gene is not imprinted [25], loss or alteration of
HERC2 expression and, thus, of HERC2 function do not
appear to be involved in the development of PWS and AS,
respectively.
With the exception of HERC5, very little is known about
the potential physiological functions of “small HERCs”
[10]. HERC5 was originally isolated in a yeast two-hybrid
screen as a Cyclin E binding protein, though the physio-
logical relevance of this observation remains unclear [26].
More recently, it was shown that HERC5 expression is
upregulated in response to pro-inflammatory stimuli and
that HERC5 acts as an E3 ligase for ISG15, a ubiquitin-like
protein that is expressed upon stimulation of cells with
interferon [10,27,28]. These data indicate that HERC5
plays an important role in the immune response.
Nedd4/Nedd4-like E3s
The human Nedd4/Nedd4-like E3 subfamily consists of
nine members with respective orthologs in mice. Family
members share a common structure: an N-terminal cal-
cium-dependent phospholipid binding C2 domain, two
to four WW domains (a highly conserved protein domain
that binds to proline-rich regions) and the HECT domain
(see figure 1) (for recent reviews on Nedd4/Nedd4-like
proteins see [11,12]). The diversity of this family is further
enhanced by alternative splicing of some (possibly all)
family members. Nedd4/Nedd4-like E3s are involved in
various pathways including endocytosis [29], degradation
of membrane proteins [30], control of cell growth [31]
and virus budding [32]. It is, therefore, not surprising that
Nedd4/Nedd4-like E3s have been involved in several
pathologies including hypertension [30], cancer [33] and
defects in the immune system [34]. In the following, we
will focus on Nedd4-1, Nedd4-2, Smurfs and Itch. All
these appear to be ubiquitously expressed, though within
the tissues they are likely to be differentially expressed, as
shown for Nedd4-1 and Nedd4-2 [35-38]. They are
mostly cytosolic proteins [39,40], although Smurf2, for
example, can be localized into the nucleus when tran-
siently expressed [41]. In addition, these proteins can
bind via their C2 domain to cell membranes, as shown for
Nedd4-1, which can interact with annexin 13 in a Ca2+-
dependent fashion and thereby be targeted to the apical
membrane of epithelial MDCK cells [42].
Nedd4-1, also referred to as Nedd4 (neuronal precursor
cell expressed developmentally downregulated 4), is the
founding member of the Nedd4/Nedd4-like E3 family
and was originally identified in a subtractive screen using
mRNAs derived from different stages of brain develop-
ment [43]. Although Nedd4-1 was originally described as
a protein containing three WW domains [44], it is now
evident that there exist multiple alternative transcripts
encoding different forms of Nedd4-1 that do or do not
have the C2 domain and which possess varying numbers
of WW domains.
Table 1: Summary of HECT E3s discussed
Chromosomal 
localization
Potential substrate proteins Mouse model Human disease
HERC1 15q22 TSC2 n.a. Tuberous sclerosis complex (?)
HERC2 15q13 Unknown Neuromuscular and spermatogenic defects; 
juvenile lethality
?
HERC5 4q22 Unknown n.a. ?
Nedd4-1 15q21 PTEN, ENaC, viral Gag proteins, numerous 
membrane transport proteins or receptors
n.a. Liddle's syndrome (?)
Retroviral infection (?)
Cancer (?)
Nedd4-2 18q21 ENaC, Nav 1.5, numerous membrane transport 
proteins
n.a. Liddle's syndrome (?)
Retroviral infection (?)
Smurf1 7q21-31 Smad1, Smad5 Bone homeostasis Bone homeostasis (?)
Smurf2 17q22-23 Smad1, Smad2, SnoN, TGF-β receptor Double knockout with Smurf1; embryonic lethal Cancer (?)
Itch 20q11.22-11.23 JunB, c-jun, PKC-θ PLC-γ1, p63, p73 Defects in Th2 cell differentiation and tolerance Th2 cell allergy (?)
E6-AP 15q11-13 Bak, Blk, HHR23, Mcm7, AIB1
In complex with the HPV E6 oncoprotein: p53, 
PDZ domain-containing proteins (e.g. hDlg, 
Scribble, MAGI-1), NFX1-91
AS-like phenotype AS
Cervical cancer
EDD 8q22.3 TopBP1, Paip2 Defects in yolk sac and allantoic vascular 
development; embryonic lethal
Cancer (?)
HECTH9 Xp11.22 histones, Mcl-1, c-Myc, p53 n.a. Cancer (?)
n.a., not available; ?, link to human disease has not been reported; (?), the respective HECT E3 has been linked to the respective disease but it remains unclear as to whether 
it is causally involved. For references, see text.BMC Biochemistry 2007, 8(Suppl 1):S6 http://www.biomedcentral.com/1471-2091/8/S1/S6
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Both Nedd4-1 and Nedd4-2 (a close relative) have been
proposed to play a role in Liddle's syndrome (a rare hered-
itary form of hypertension), the budding of retroviruses
including HIV-1 and HTLV-1 (which are etiologically
associated with AIDS and adult T-cell leukemia, respec-
tively) and T-cell receptor (TCR) signaling [45-47].
Known ubiquitylation substrates of Nedd4-1 or Nedd4-2
include ENaC (Liddle's syndrome), viral GAG proteins
(retroviral budding), PKC-θ and PLC-γ1 (TCR signaling),
and PTEN [31,45-47]. In many cases, PY motifs in the sub-
strate proteins serve as binding sites for the WW domains
of Nedd4-1 and/or Nedd4-2.
Smurfs (Smurf1 and Smurf2) were originally identified in
a yeast two-hybrid screen as proteins that, via WW
domains, interact with a PY motif in Smad-1, a protein
involved in TGF-β/BMP signaling [48]. The TGF-β super-
family comprises approximately 40 members including
TGF-β, activins, nodals and the bone morphogenetic pro-
teins (BMPs) [49], and mutations in TGF-β pathway com-
ponents are associated with several human diseases
including cancer and osteoporosis. TGF-β ligand receptors
are heterodimers composed of type I and type II class
receptors and have Ser/Thr kinase activity. Heterodimeri-
zation is induced by ligand binding and results in type II
receptor-mediated phosphorylation of the type I receptor,
which in turn becomes activated and phosphorylates ser-
ine residues on receptor-regulated Smads (R-Smads)
(Smad-1, -2, -3, -5, and -8) (see figure 2). Smad-1, -5 and
-8 are involved in the BMP pathway, whereas Smad-2 and
Smad-3 are signaling components of the TGF-β pathway.
Once phosphorylated, R-Smads complex with the com-
mon co-Smad, Smad-4, and translocate into the nucleus,
where they regulate transcription. Furthermore, inhibitory
Smads (I-Smads) (Smad-6 and Smad-7) interfere with
TGF-β and BMP signaling by competing with R-Smads for
association with type I receptors or by targeting receptors
for ubiquitin-mediated degradation (see figure 2).
Smurf1 and Smurf2 act at different levels of the TGF-β/
BMP signaling pathways. Smurf1 targets the BMP signal-
ing proteins Smad-1 and Smad-5 for ubiquitin-dependent
degradation [48], whereas Smurf2 associates with Smad-1
and Smad-2, inducing a decrease in the levels of these two
proteins [50]. Importantly, Smad-2 activation results in
an increased interaction with Smurf2, leading to its pro-
teasome-mediated degradation in the nucleus [51], sug-
gesting that Smurf2 is important for termination of TGF-β
signaling. However, Smurf2 may also facilitate TGF-β sig-
naling, since Smad-2 recruits Smurf2 to the transcrip-
tional co-repressor SnoN [52], an inhibitor of the TGF-β
transcriptional response, resulting in SnoN ubiquitylation
and degradation (see figure 2). Yet another mechanism
involves the I-Smad Smad-7. Upon binding, Smad-7–
Smurf2 are exported from the nucleus and interact with
the TGF-β receptor. In concert with the E2 enzyme
UbcH7, this results in Smad-7 ubiquitylation, triggering
internalization and degradation of both Smad-7 and the
receptor [41]. Similar to Smurf2, Smurf1 is also recruited
by Smad-7 to the TGF-β receptor [53]. Finally, both Smad-
6 and Smad-7 can mediate translocation of Smurf1 to
BMP receptors, leading to ubiquitylation and degradation
of these receptors [54].
Itch (also referred to as AIP4) was originally identified as
the protein encoded by the itchy locus (located on chro-
mosome 2) in non-agouti lethal 18H mice [55]. The phe-
notype of both these and genetically engineered Itch null
mice indicate that Itch is crucially involved in Th2 cell dif-
ferentiation and anergy. In response to stimulation with
anti-CD3, or anti-CD3 plus anti-CD28, T-cells can
undergo chronic activation, which is accompanied by
increased production of IL-4 and IL-5, resulting in a
biased differentiation of CD4+ cells into Th2 cells [34].
During T-cell differentiation, Itch binds via its WW
domains to the PPXY motif of Jun-B and/or c-Jun, pro-
moting their ubiquitylation and subsequent proteasomal
degradation. Since the transcription factors Jun-B and c-
Jun are intrinsically involved in the regulation of Th2
cytokine expression (including that of IL-4), this indicates
that Itch is involved in the negative control of Th2 cell dif-
ferentiation [34]. Indeed, the Th2-dependent serum con-
centrations of IgG1 and IgE are increased in itchy mice
[34].
T-cell anergy, a process contributing to self-immune toler-
ance, is a state of unresponsiveness that is achieved when
the TCR is engaged without co-stimulation of accessory
molecules such as the CD86 receptor [56,57]. In the
absence of co-factors, TCR engagement is sufficient to
stimulate mobilization of intracellular free calcium ions,
leading to activation of calcineurin. In turn, calcineurin
dephosphorylates the transcription factor NF-AT1, result-
ing in its activation and subsequent stimulation of the
transcription of “anergy genes”, whose products keep T-
cells in an anergic state [58]. Among several signaling pro-
teins and other ubiquitin-protein ligases (Grail, Cbl-B),
Itch and Nedd4 are induced by this calcium/calcineurin
signaling pathway [47]. Itch and Nedd4 become mem-
brane-associated (most likely via their C2 domain) and
bind and monoubiquitylate PKC-θ and PLC-γ1, both of
which are important for TCR signaling and immunologi-
cal synapse formation. Monoubiquitylated PKC-θ and
PLC-γ1 are in turn targeted via the ESCRT pathway into
lysosomes and degraded [47].
The E3 activity of Itch is regulated by phosphorylation.
Fyn kinase-mediated tyrosine phosphorylation has a neg-
ative effect on Itch activity [59], whereas phosphorylation
of Itch by the MEKK1/JNK1 pathway results in Itch activa-BMC Biochemistry 2007, 8(Suppl 1):S6 http://www.biomedcentral.com/1471-2091/8/S1/S6
Page 5 of 14
(page number not for citation purposes)
Role of Smurfs in the TGF-β/BMP pathways Figure 2
Role of Smurfs in the TGF-β/BMP pathways. TGF-β ligand stimulates heterodimerization of type I and type II Ser/Thr kinase 
receptors (labeled R-I and R-II), leading to phosphorylation of type I receptor by type II receptor. This recruits receptor regu-
lated Smads (R-Smads), which become phosphorylated. Upon phosphorylation, R-Smads interact with the common Smad (co-
Smad), Smad4, and the complex translocates into the nucleus, where it interacts with co-factors and stimulates transcription of 
genes involved in differentiation. The pathway is negatively regulated by inhibitory Smads (I-Smads), by SnoN and by Smurfs. 
Smurfs can interact with and ubiquitylate R-Smads and can be recruited by I-Smads to the receptor, where they induce recep-
tor ubiquitylation and internalization. Furthermore, Smurfs are also involved in SnoN ubiquitylation, and thus are also able to 
act as positive regulators of this pathway.BMC Biochemistry 2007, 8(Suppl 1):S6 http://www.biomedcentral.com/1471-2091/8/S1/S6
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tion and, consequently, in increased turnover of Jun-B
and c-Jun (60). Furthermore, results obtained with mice
expressing MEKK1ΔKD, a catalytically inactive MEKK1
mutant, are consistent with the notion that phosphoryla-
tion of Itch is required to negatively control Th2 cell acti-
vation. Additionally, Th2 cells that either express an
inactive MEKK1 mutant or are devoid of JNK1 or Itch can-
not become immune tolerized, whereas Th1 tolerance is
not affected [61]. Thus, the MEKK1/JNK1/Itch pathway is
important for Th2 cell differentiation and Th2 tolerance
(T-cell anergy).
Itch has also been implicated in TNFα signaling [62]. The
biological outcome of TNFα signaling depends on the bal-
ance between the NF-κB and JNK signaling pathways,
with NF-κB promoting survival and JNK enhancing cell
death. It has been shown that TNFα-mediated JNK activa-
tion results in phosphorylation and activation of Itch. Itch
then targets the NFκB-induced anti-apoptotic protein c-
FLIP for ubiquitin-dependent degradation. Importantly,
JNK1 or Itch null mice are resistant to TNFα-induced
acute liver failure and cells derived from these mice are
not proficient in inducible c-FLIP degradation [62].
Itch has also been shown to bind to, ubiquitylate and
thereby negatively regulate p63 and p73, which are mem-
bers of the p53 family of transcription factors, suggesting
a role for Itch in the control of the cell cycle and apoptosis
[63-65]. Interestingly, p73 was also shown to be ubiquit-
ylated by Nedd4-2 [66]. Furthermore, p53 has recently
been shown to be ubiquitylated by WWP1, another
Nedd4/Nedd4-like E3 enzyme [67].
SI-HECT E3s
The best studied members of this HECT E3 subgroup are
E6-AP, EDD and HECTH9, all of which have been associ-
ated with human disease. mRNA of E6-AP, which repre-
sents the founding member of the HECT family of E3s
[1,2,68], is ubiquitously expressed and the protein is
found in the cytoplasm and nucleus. Mutations within the
encoding gene, UBE3A (located on chromosome 15q11-
13), that interfere with the E3 activity of E6-AP have been
etiologically associated with the development of AS
[69,70]. Importantly in this respect, imprinting of the
UBE3A gene is restricted to the brain, whereas it is biallel-
ically expressed in all other tissues [71,72]. E6-AP (E6-
associated  protein) was originally isolated as a protein
that binds to the E6 oncoprotein of human papillomavi-
ruses (HPVs) etiologically associated with malignant can-
cers of the anogenital tract, most notably cervical cancer
[68,73].
E6-AP is hijacked by E6 to target several cellular proteins
for ubiquitin-dependent degradation. Known substrates
of the E6–E6-AP complex include the tumor suppressor
p53, the PDZ domain-containing protein Scribble and
NFX1-91, a transcriptional repressor of the gene encoding
hTERT, the rate-limiting catalytic subunit of telomerase
[74-76] (for reviews, see [77,78]). Importantly, cell cul-
ture studies and studies with transgenic mice clearly indi-
cate that the ability of E6 to interact with both E6-AP and
PDZ domain-containing proteins is crucial for its onco-
genic potential (see Disease, mutation, expression, knockout
- SI-HECT E3s). Furthermore, E6-AP may not only be uti-
lized by E6 but, in addition, may represent a direct target
for E6, since binding of E6 targets E6-AP for ubiquityla-
tion and degradation [79]. However, the physiological rel-
evance of this observation remains unclear. Similarly,
since cell culture systems that allow the efficient propaga-
tion of HPVs are not available, the significance of the E6–
E6-AP interaction for the viral life cycle is not known.
In contrast to the situation in HPV-positive cancer cells,
the physiological role of E6-AP in normal (i.e. HPV-nega-
tive) cells remains elusive. Several E6-independent sub-
strates of E6-AP have been reported, including HHR23A
and HHR23B (the human orthologs of Saccharomyces cer-
evisae Rad23), Blk (a member of the Src family of non-
receptor tyrosine kinases), Bak (a human pro-apoptotic
protein), Mcm7 (which is involved in DNA replication)
[77,78] and AIB1 (a steroid receptor coactivator) [80].
However, the physiological relevance of these interactions
remains to be shown.
Human EDD (E3 identified by differential display) repre-
sents an ortholog of HYD, the Drosophila hyperplastic
discs tumor suppressor gene product. EDD mRNA is
expressed in many tissues and is frequently overexpressed
in breast and ovarian cancers, suggesting a possible role in
tumor development [81-83]. The EDD protein consists of
2799 amino acid residues and contains three putative
nuclear localization sequences, an N-terminal UBA
domain (which mediates EDD's interaction with ubiqui-
tin), a central UBR1-like zinc finger motif and a PABC
domain (a peptide binding domain found in the poly(A)-
binding protein PABP) [81,84-87]. EDD has been shown
to bind to and ubiquitylate the topoisomerase II beta-
binding protein TopBP1, and to bind to and potentiate
progesterone receptor-mediated transcriptional transacti-
vation [85,86]. More recently, it has been reported that
EDD binds to the DNA damage checkpoint kinase Chk2
and acts upstream of Chk2 [88], supporting the notion
that EDD is involved in pathways regulating the DNA
damage response. Furthermore, it has been demonstrated
that downregulation of PABP results in EDD-mediated
degradation of the PABP-associated protein Paip2, which
interferes with translation by displacing PABP from
mRNA [89]. This indicates that EDD is involved in con-
trolling the activity of PABP and, thus, in controlling
translational efficiency.BMC Biochemistry 2007, 8(Suppl 1):S6 http://www.biomedcentral.com/1471-2091/8/S1/S6
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HECTH9 mRNA is expressed in many tissues and the pro-
tein appears to be mainly located in the nucleus. Impor-
tantly, HECTH9 is overexpressed in several different
tumors, suggesting that deregulation of HECTH9 activity
contributes to cancerogenesis [90]. HECTH9 was initially
reported to interfere with p53-mediated transcriptional
transactivation [91]. However, the physiological signifi-
cance of this observation remained unclear, since it turned
out that the protein studied (termed UREB1 at the time)
represented a significantly N-terminally truncated version
of HECTH9. Recently, several groups reported on the
identification of substrate proteins of full-length
HECTH9. These included p53, histones, the anti-apop-
totic protein Mcl-1 and the proto-oncoprotein c-Myc
(note that the respective authors referred to HECTH9 with
different names, including E3 histone, ARF-BP1 (ARF-
binding protein 1) and MULE (Mcl-1 ubiquitin ligase
E3)) [90,92-94]. Note that p53, Mcl-1 and c-Myc were
identified as substrates in vivo using ubiquitylation assays
in overexpression experiments in cultured cells, and that
these findings were supported by in vitro assays. HECTH9
has only been shown to ubiquitylate histones using in
vitro ubiquitylation assays.
HECTH9 consists of 4374 amino acid residues and con-
tains three domains known to serve as protein–protein
interaction sites: a BH3 domain, a WWE domain and a
UBA domain (for a recent review on HECTH9, see [95]).
The BH3 domain is required for the interaction of
HECTH9 with Mcl-1 [94], whereas the interactions sites
for p53 and c-Myc have not been mapped in detail. Inter-
estingly, while HECTH9-mediated ubiquitylation targets
p53 and Mcl-1 for proteasomal degradation, c-Myc is not
targeted for degradation by HECTH9. Instead, HECTH9
modifies c-Myc with ubiquitin chains that are linked via
lysine residue 63 (K63) of ubiquitin [90] and serve non-
proteolytic roles [7-9]. Specifically, HECTH9-mediated
ubiquitylation of c-Myc appears to be required for trans-
activation of multiple target genes of c-Myc and induction
of cell proliferation. Taken together, the available data
indicate that HECTH9 has pro-proliferative activities.
Disease, mutation, expression, knockout
HERC E3s
To date, none of the members of the HERC E3 subfamily
has been etiologically associated with human disease and
transgenic HERC mice have not been reported. In the late
1990s, however, it was shown that so-called rjs (runty,
jerky, sterile) mice harbor mutations in the Herc2 gene
[23,96]. Rjs mice (commercially available from The Jack-
son Laboratory, Maine, USA) have neuromuscular and
spermatogenic abnormalities and are characterized by
defects in growth, movement coordination (jerky gait)
and fertility. Importantly, one of the rjs mutants isolated
expresses a C-terminally truncated form of HERC2 lacking
part of the C-terminal HECT domain [96]. This indicates
that loss of HERC2 E3 activity is responsible for the
observed phenotype. Although deregulated expression of
human HERC2 has not been causally associated with any
human disease, identification of HERC2 substrate pro-
teins may eventually reveal whether or not HERC2 plays a
role in human disease.
Nedd4/Nedd4-like E3s
Liddle's syndrome is characterized by early onset of severe
hypertension, hypokalemia, metabolic alkalosis and low
circulating levels of renin and aldosterone [97,98].
Patients are treated with a low Na+ diet and administra-
tion of triamterenes, which are specific inhibitors of
ENaC. All the available data suggest that Na+ reabsorption
by epithelia of the distal nephron is deregulated in this
disease. Normally, such cells express at their apical side
(facing the urinary compartment) ENaC, which allows
entry of Na+ into the cell, and on the basolateral side the
Na+,K+-ATPase, which extrudes Na+ out of the cell into the
blood compartment. This Na+ transport is highly regu-
lated by the renin-angiotensin-aldosterone system. In Lid-
dle's syndrome patients, genes encoding ENaC subunits
are mutated [99,100]. ENaC is a transmembrane protein
that is composed of three homologous subunits, which
assemble into tetramers (2α1β1γ). The C-terminus of each
subunit contains PY motifs that serve as binding sites for
the WW domains of Nedd4-1 and/or Nedd4-2 [101].
Upon binding, Nedd4-1/Nedd4-2 ubiquitylate the N-ter-
mini of the ENaC subunits, leading to ENaC internaliza-
tion and degradation by the endosomal/lysosomal system
[36,37,45]. In Liddle's syndrome patients, a PY motif is
mutated or deleted either in the β- or γ-subunit [99,100],
leading to impaired interaction with Nedd4-1/Nedd4-2
and, consequently, accumulation of ENaC at the plasma
membrane.
The majority of evidence, including that derived from co-
localization [38] and RNAi studies [102], indicates that
Nedd4-2 is the physiologically relevant regulator of ENaC
in the kidney. Importantly, Nedd4-2 is a substrate of the
aldosterone-induced kinase Sgk1, a key regulator of Na+
transport. Phosphorylation of Nedd4-2 creates binding
sites for 14-3-3 proteins, which interfere with ENaC–
Nedd4-2 interaction, causing an increase in channels at
the cell surface [103-105]. Furthermore, polymorphisms
in the Nedd4-2 gene have been associated with hyperten-
sion [106]. However, definite proof that Nedd4-2 controls
Na+ transport in the distal nephron will have to await its
inactivation and analysis in a conditional transgenic
mouse knockout model or unambiguous genetic linkage
of the Nedd4-2 locus to Liddle's syndrome or other forms
of hypertension.BMC Biochemistry 2007, 8(Suppl 1):S6 http://www.biomedcentral.com/1471-2091/8/S1/S6
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Retroviral budding takes advantage of the cellular
machinery that targets proteins for lysosomal degradation
via the multiple vesicle body (MVB) pathway (for reviews,
see [107,108]). Essentially, late domains of viral GAG pro-
teins contain a P(S/T)AP motif, a PY motif, or a tyrosine-
based sorting motif (YPx(n)L), which recruit components
of the MVB machinery (e.g. Tsg101) and promote virus
budding. Although viral PY motifs bind to Nedd4 family
members, it is not yet clear how this promotes particle
release. Ubiquitylation of GAG could recruit the MVB
machinery, for example via binding to Tsg101 or to other
ubiquitin binding proteins of the ESCRT pathway. Alter-
natively, since Nedd4 and Tsg101 can interact with each
other, Nedd4 could recruit Tsg101 to the GAG protein,
inducing virus budding [109]. Furthermore, studies using
HTLV-1 GAG, which contains both a PY motif and a P(S/
T)AP motif (which binds Tsg101), showed that mutation
of the PY motif leads to accumulation of the virus at the
plasma membrane, whereas mutation of the P(S/T)AP
motif leads to accumulation in endosomes. This suggests
that HTLV-1 first interacts at the plasma membrane with
Nedd4 and later with Tsg101 in endosomes [32]. In any
case, Nedd4 family members appear to play a crucial role
in retroviral budding and, thus, in the spreading of these
viruses.
TGF-β has both tumor suppressive and tumor promoting
effects [110]. Thus, both inappropriate inactivation and
activation of Smurfs could contribute to cellular transfor-
mation and cancerogenesis. Indeed, Smurf2 overexpres-
sion in esophageal squamous cell carcinoma correlates
with poor prognosis [33]. Similarly, oncogenic missense
mutations in the Smad-2 or Smad-4 genes target the
respective mutant proteins for increased ubiquitylation
and degradation when compared with the wild-type pro-
teins, thereby interfering with TGF-β signaling [111].
Although the E3s involved in the degradation of the Smad
mutants have not yet been identified, it was shown that
RNF11, a RING finger E3 that is highly expressed in inva-
sive breast cancer [112], interacts with Smurf2 and targets
it for ubiquitylation and degradation. Furthermore,
RNF11 can interfere with Smurf2-mediated ubiquityla-
tion of the TGF-β receptor. By blocking Smurf2 activity,
RNF11 could enhance TGF-β signaling and its tumor-pro-
moting activities in certain tissues.
Since both TGF-β and BMPs signal through Smads, it is
not surprising that Smurfs, especially Smurf1, affect bone
homeostasis. Overexpression of Smurf1 interferes with
BMP-induced osteoblast differentiation [113,114],
whereas RNAi-mediated downregulation of Smurf1
expression, or expression of catalytically inactive Smurf1,
enhances osteoblast differentiation [113,115]. Further-
more, transgenic mice overexpressing Smurf1 (generated
by the Chen Group, University of Rochester, USA) display
significantly reduced bone formation [114]. These find-
ings are in agreement with the notion that Smurf1 con-
trols the levels of Smad-1 and/or Smad-5 (see Localization
and Function - Nedd4/Nedd4-like E3s), as well as the levels
of the osteoblast-specific transcription factor Runx2 [114-
116]. The strongest evidence supporting a role for Smurfs
in bone homeostasis comes from Smurf1 null mice (gen-
erated by the Zhang Group, National Cancer Institute,
Bethesda, USA) [117]. These mice are viable, develop nor-
mally and have a similar life expectancy to wild-type mice.
However, starting from approximately four months of
age, Smurf1 null mice show an increase in bone mass
caused by enhanced osteoblast activity, indicating that
Smurf1 is important for bone-forming activities in mature
osteoblasts. Surprisingly, neither BMP signaling nor
Runx2 activity seem to be affected in Smurf1 null mice;
rather the JNK signaling pathway is constitutively active,
resulting in enhanced expression of JNK-responsive genes.
Smurf1 interacts with MEKK2, an upstream activator of
JNK, and targets it for ubiquitin-dependent degradation,
suggesting that deregulated MEKK2 activity is responsible
for the phenotype of Smurf1 null mice. Indeed, expres-
sion of constitutively active MEKK2 or JNK or inactive
MEKK2 in osteoblasts demonstrates that these kinases reg-
ulate osteoblast activity. The lack of effect of Smurf1 inac-
tivation on the BMP pathway could be explained by
compensatory functions of Smurf2. Indeed, Smurf1 null
mice show increased Smurf2 expression. Furthermore,
Smurf1/Smurf2 double knockout mice (generated by the
Zhang Group, National Cancer Institute, Bethesda, USA)
are embryonic lethal, supporting the idea that Smurf1 and
Smurf2 have overlapping or compensatory functions
[117]. Although involvement of Smurf1 in human pathol-
ogies with dysregulated bone homeostasis (such as oste-
oporosis) remains to be demonstrated, the fact that
Smurf1 inactivation has no effect on the maintenance of
skeletal integrity could aid development of therapeutic
strategies for treating age-related bone loss such as oste-
oporosis.
In Itchy mice (generated by the Copeland/Jenkins Group
at the National Cancer Institute, Frederick, USA; see Local-
ization and Function - Nedd4/Nedd4-like E3s), Itch is inacti-
vated by gene inversion, alongside promoter inactivation
of the agouti gene, leading to a darker color coat [55].
Depending on the genetic background, the mice present
two different but related phenotypes: on a JC/Ct back-
ground they display an inflammatory disease of the large
intestine, whereas on a C57L/6J background they present
a fatal disease involving changes in lung, spleen, lymph
nodes, skin, ear, thymus and stomach. In each organ, the
phenotype suggests hyperactivation of processes typical
for chronic inflammation. Moreover, Itchy mice are char-
acterized by skin and ear scarring, caused by constant itch-
ing when older than 16 weeks, and display larger spleensBMC Biochemistry 2007, 8(Suppl 1):S6 http://www.biomedcentral.com/1471-2091/8/S1/S6
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and lymph nodes, likely due to hyperproliferation of lym-
phocytes. This phenotype points to a crucial role for Itch
in the negative control of the immune system. Indeed, as
discussed in Localization and Function - Nedd4/Nedd4-like
E3s, the Itch pathway appears to be particularly important
for the regulation of Th2 cell differentiation; thus, Th2 tol-
erance and defects in this pathway could contribute to
Th2 cell-mediated allergies. These notions are supported
by experiments performed with T-cells derived from Itchy
mice [34].
SI-HECT E3s
E6-AP represents a prime example supporting the notion
that deregulation of components of the ubiquitin conju-
gation system contributes to human disease: inappropri-
ate activation of E6-AP ("gain of function") contributes to
the development of cervical cancer and inactivation of E6-
AP ("loss of function") results in AS.
Infection with certain HPV types represents the most sig-
nificant risk factor for the development of cervical cancer,
the second most frequent cancer in women worldwide
with approximately 400,000 new cases each year (for
review see [73]). The suggested ability of the HPV E6
oncoprotein to utilize E6-AP to target p53 and other cellu-
lar proteins for degradation is supported by several obser-
vations. Firstly, transgenic mouse models indicate that
HPV-induced tumorigenesis is crucially dependent on
both ablation of p53 activity and the interaction of E6
with PDZ domain proteins [118,119]. Secondly, in con-
trast to many other tumor types (approximately 40% of
all human tumors harbor a mutated p53 gene), the p53
gene is very rarely mutated in cervical carcinomas [73,78].
Thus, E6/E6-AP-induced degradation of p53 can be con-
sidered functionally equivalent to inactivation of p53 by
mutation of the p53 gene, although the situation in HPV-
positive cancers may be somewhat more complicated (for
detailed discussion of this issue, see [78]). Thirdly, inter-
ference with E6-AP expression by antisense RNA-based
approaches or by RNAi results in accumulation of p53
and activation of its transcriptional and growth-suppres-
sive properties [120-123].
AS was first described in 1965 by the pediatrician Harry
Angelman [124,125]. It is a genetic disorder with an inci-
dence of approximately 1 in 10000 to 1 in 40000 and is
characterized by mental retardation, movement or bal-
ance disorder, characteristic abnormal behaviors and
severe limitations in speech and language. As discussed in
Localization and Function - SI-HECT E3s, AS has been
linked to chromosome 15q11-13, which contains the
UBE3A gene [25,69,70]. All of the genetic abnormalities
associated with AS affect expression of the maternal
UBE3A gene and/or the ubiquitin ligase activity of E6-AP.
Development of AS appears to be the result of several
genetic mechanisms, with deletion of the 15q11-13
region of the maternal chromosome accounting for
approximately 70 percent of cases. Other mechanisms
include uniparental paternal disomy, defects in imprint-
ing and single point mutations in the UBE3A gene
[25,125,126]. In this context, it should be noted that E6-
AP affects the activity of nuclear hormone receptors and
that this property does not appear to be related to its E3
function [127]. However, the relevance of this function
for the development of AS or cervical cancer is unclear
(e.g. this property is not affected in E6-AP mutants derived
from AS patients with point mutations in the UBE3A
gene). The notion that loss of E6-AP activity is responsible
for the development of AS is strongly supported by trans-
genic mouse models [128,129]. Furthermore, studies in
mice have shown that, similar to the situation in humans,
the murine Ube3a gene encoding E6-AP is biallelically
expressed in all somatic cells with the exception of
Purkinje cells (cerebellum), hippocampal neurons and
mitral cells of the olfactory bulb, in which the paternally
derived Ube3a gene is silenced [130]. Finally, it should be
noted that in E6-AP null mice (generated by the Beaudet
Group, Baylor College of Medicine, USA and commer-
cially available from The Jackson Laboratory, Maine, USA
and the Wagstaff Group, University of Virginia, USA),
cytoplasmic levels of p53 are significantly increased in
postmitotic neurons. However, since all available data
indicate that, in the absence of the HPV E6 oncoproteins,
E6-AP does not play a prominent role in p53 degradation,
it seems likely that the observed increase in p53 levels is
an indirect rather than a direct effect of loss of E6-AP
expression.
EDD mRNA is frequently overexpressed in breast and
ovarian cancers [81,82]. In addition, the EDD gene was
reported to be mutated in mammary ductal carcinoma
[83]. Since the hyd gene, which encodes the proposed Dro-
sophila ortholog of EDD, was originally identified as a
tumor suppressor gene [131], these findings indicate that
deregulation of EDD activity could contribute to tumor
development. However, etiological association of EDD
with human disease remains to be shown. Conventional
EDD null mice (generated by the Watts Group, Garvan
Institute of Medical Research, Australia) are embryonic
lethal [132], though the molecular mechanisms leading
to embryonic death remain unclear. Thus, the generation
of conditional transgenic mouse models and further char-
acterization of the molecular functions of HYD in Dro-
sophila[131,133] will be important in the elucidation of
the role of EDD in cell regulatory pathways.
As discussed in Localization and Function - SI-HECT E3s,
HECTH9 is overexpressed in various cancers and acts as a
positive effector of cell proliferation, suggesting that the
protein could be a promising target for anti-cancer thera-BMC Biochemistry 2007, 8(Suppl 1):S6 http://www.biomedcentral.com/1471-2091/8/S1/S6
Page 10 of 14
(page number not for citation purposes)
pies. This notion is supported by the observations that
HECTH9 (i) plays an important role in p53 degradation;
(ii) is negatively regulated by the human tumor suppres-
sor p14ARF and (iii) activates the proto-oncoprotein c-
Myc. Furthermore, RNAi-mediated downregulation of
HECTH9 expression interferes with the growth of p53 null
cells (summarized in [95]). Taken together, these observa-
tions indicate that HECTH9 has both p53-dependent and
p53-independent pro-proliferative properties. Whether or
not the p53-independent properties of HECTH9 are
related to its activation of c-Myc and whether p14ARF
affects c-Myc activation remain to be determined. Further-
more, it should be noted that the observation that
HECTH9 targets the anti-apoptotic protein Mcl-1 for deg-
radation [94] is not consistent with its pro-proliferative
properties. In any case, the generation of conventional
and conditional transgenic mouse models for the murine
ortholog of HECTH9 will provide valuable insight into
the role of this protein in cell regulatory pathways.
Disease targets and ligands
As discussed in this review, several HECT E3s have been
proposed to be involved in the development of human
disease. However, ligands targeting HECT E3s have not yet
been described, which may (at least in part) be due to the
fact that there is only limited information to date on both
physiologically relevant substrate proteins of HECT E3s
and the actual physiological function of HECT E3s (i.e.
which HECT E3s are involved in which cellular path-
ways). Thus, in the following, we briefly discuss those
HECT E3s that, based on current knowledge, may repre-
sent potential targets for therapeutic approaches.
HERC E3s
The HERC1 target protein TSC2 [21] has been associated
with the development of the hereditary disorder tuberous
sclerosis complex (TSC). Furthermore, the half-life of
TSC2 appears to be significantly shortened in TSC patients
either by mutation in the TSC2 gene or by loss of expres-
sion of TSC1, which binds to and stabilizes TSC2 [21].
Thus, if TSC2 stability is mainly controlled by HERC1
(which remains to be shown), HERC1 represents a puta-
tive target in the treatment of TSC.
Although HERC5 has not yet been associated with human
disease, the available data indicate that HERC5 plays an
important role in the immune response [27,28] and could
thus represent a potential therapeutic target. However, the
actual physiological function and physiologically relevant
substrate proteins of HERC5 have not yet been delineated.
Nedd4/Nedd4-like E3s
There is considerable evidence supporting the notion that
the activity of ENaC is regulated by Nedd4-2 and deregu-
lated in many cases of Liddle's syndrome [30,45,97-
100,102]. However, since deregulation of ENaC activity in
Liddle's syndrome patients is due to the inability of the
respective ENaC mutants to interact with Nedd4-2, ENaC
rather than Nedd4-2 appears to be a relevant target for
therapeutic approaches.
Smurf2 has been associated with the development of
tumors. However, the notion that both inappropriate acti-
vation and inactivation of Smurf2 could contribute to
cancerogenesis [33,111,112] will need to be taken into
account when considering Smurf2 as a potential target for
therapeutic approaches.
Genetic experiments in mice indicate that Smurf1 nega-
tively controls osteoblast activity and that Smurf1 inacti-
vation does not affect skeletal integrity. Thus, if Smurf1
plays a similar role in humans, then inactivation of the
protein could prove beneficial for the treatment of age-
related bone loss.
SI-HECT E3s
E6-AP has been etiologically associated with the develop-
ment of AS [69-72,125,126]. However, since loss of E6-AP
activity is observed in AS patients, substrate proteins of
E6-AP rather than E6-AP itself represent targets for thera-
peutic approaches. In addition, E6-AP is hijacked by the
E6 oncoprotein of cancer-associated HPVs to deregulate
the activity of several important cell regulatory proteins
[74-78]. Thus, the E6/E6-AP interaction could provide a
feasible target for molecular approaches in the treatment
of cervical cancer. However, in this particular case, E6
rather than E6-AP appears to be the target of choice, for
obvious reasons [78].
Similar to E6-AP, deregulation of EDD [81-83] and
HECTH9 (summarized in [95]) has been associated with
cancerogenesis. Thus, interfering with the interaction
between these proteins and their respective substrate pro-
teins (e.g. EDD and Paip2, HECTH9 and p53), or with
their E3 activity, could prove beneficial in the treatment of
the respective cancers.
New frontiers in drug discovery
Although HECT E3s are (potentially) involved in the
development of human disease, it remains to be deter-
mined if HECT E3s can indeed serve as targets for molec-
ular therapeutic approaches. To do so, the following
issues need to be addressed:
(i) What are the substrates of the respective E3? In which
pathways is the respective E3 involved and in which tis-
sues? This is certainly one of the most challenging tasks
and requires extensive proteomic efforts. In fact, the phys-
iologically relevant substrate proteins of most HECT E3s
are not yet known and their identification may be ham-BMC Biochemistry 2007, 8(Suppl 1):S6 http://www.biomedcentral.com/1471-2091/8/S1/S6
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pered by the notion that a given protein is recognized as a
substrate by more than one E3. However, knowledge of
the substrates and the networks involving the respective
E3s will be invaluable when designing molecular thera-
pies.
(ii) Is inactivation or inappropriate activation of HECT E3
activity involved in disease development? If the former is
the case, potential therapeutic strategies will further
depend on whether E3 activity is lost by genetic mutation
(e.g. loss of E6-AP activity in AS) or by alteration of the
activity of regulators of the respective E3. In such cases, the
substrate proteins or proteins that regulate the activity of
HECT E3s (e.g. Sgk1 kinase, which negatively affects
Nedd4-2/substrate interaction) rather than the E3s them-
selves may be the most appropriate targets. If inappropri-
ate activation of a HECT E3 contributes to disease, the
HECT E3 itself (e.g. overexpressed HECTH9 in cancer) or
activators of the E3 activity (e.g. the E6/E6-AP interaction
in cervical cancer) could be the targets of choice.
(iii) How to target HECT E3s? In principal, interference
with E3 activity can be envisioned at two levels; by target-
ing the substrate/E3 interaction or by targeting the cata-
lytic activity of HECT E3s (i.e. the HECT domain). The
notion that the former strategy can be successfully used is
supported by approaches aimed at interfering with the
interaction between p53 and one of its main regulators,
the RING finger E3 ligase Mdm2. In this case, it has been
shown that small molecules that inhibit the interaction of
p53 with Mdm2 induce p53 accumulation and activation
in tumor cells, and thus interfere with the growth of wild-
type p53-expressing tumor cells [134]. Similar strategies
can be envisioned for HECTH9, which appears to be over-
expressed in various tumors. Due to the notion that
HECTH9 has both p53-dependent and p53-independent
pro-proliferative activities, interference with HECTH9
activity could provide a strategy that may be applicable in
the treatment of tumors independent of their p53 status.
At first glance, strategies targeting the HECT domain
appear to be less attractive, since such molecules may be
rather unspecific insofar as they could interfere with the
activity of HECT E3s in general. However, structural stud-
ies have shown that, when compared with the E6-AP
HECT domain, the HECT domain of Smurf2 has a subop-
timal E2 binding pocket and that Smad-7 stimulates the
E3 activity of Smurf2 by recruiting UbcH7 to the HECT
domain [4,6]. Thus, it may be possible to identify and
develop small molecules that are specific inhibitors of dis-
tinct HECT domains.
Regardless of whether the HECT domain or the E3/sub-
strate interaction may be the target of choice, extensive
structural studies are clearly required to obtain insight
into the molecular details of the respective E3/substrate
interactions and of HECT E3-catalyzed ubiquitylation of
substrate proteins. Such information will be invaluable
when designing ligands targeting the respective HECT E3.
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